Swiss diagnostic firm Roche has launched a new test called anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for the diagnosis of prostate cancer.
Intended for the use in laboratories, the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody is designed to detect α-methylacyl-CoA racemase (AMACR) in formalin-fixed, paraffin-embedded (FFPE) tissue sections.
The new tool is validated for use with a dual stain and VENTANA Basal Cell Cocktail (34ßE12+p63) to enable easy differentiation of morphologically difficult cases such as benign, atypical or cancerous on a single slide.
The in-vitro diagnostic (IVD) primary antibody can be used on the automated slide stainers of the VENTANA BenchMark IHC/ISH series.
Roche Tissue Diagnostics head Ann Costello said: “As the second most common cancer in men, prostate cancer is a serious public health concern.
“The anti-p504s (SP116) Primary Antibody is an important tool to aid clinicians in making a more accurate diagnosis with a smaller tissue sample.”
The prostate adenocarcinoma is reported to be easily identifiable with the increased expression of biomarker, p504s or α-methylacyl-CoA racemase (AMACR).
The use of p504s in a dual stain with the VENTANA Basal Cell Cocktail is claimed to decrease the need for several slides, which is considered to be beneficial during the availability of limited tissue samples, as is the case for prostate biopsies.
Founded in 1896, Roche currently operates in more than 100 countries.
The firm develops pharmaceutical and diagnostic products for oncology, immunology, infectious diseases, ophthalmology and central nervous system disorders.
Image: Prostate carcinoma dual stained with anti-p504s (SP116) Rabbit Monoclonal Primary Antibody in red, and VENTANA Basal Cell Cocktail (34ßE12+p63) in brown. Photo: courtesy of PRNewsFoto/Roche.